22nd Century Group, Inc.: Form 10-Q for the period ended Jun 30, 2026
Filed with the SEC on Aug 14, 2026 and accepted by EDGAR at Aug 14, 2026, 16:16 ET.
Management's discussion and analysis
As filed, 27,561 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
For purposes of this Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”), references to the “Company,” “we,” “us” or “our” refer to the operations of 22nd Century Group, Inc. and its direct and indirect subsidiaries for the periods described herein.
The following MD&A should be read in conjunction with, our audited consolidated financial statements, the accompanying notes and the MD&A included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as well as our Condensed Consolidated Financial Statements and the accompanying notes included in Item 1 of this Form 10-Q. Note references are to the notes to consolidated financial statements included in Item 1 of this Form 10-Q.
All historical share and per-share amounts reflected throughout this section have been adjusted to reflect prior reverse stock splits. The par value per share of our common stock was not affected.
All figures reported below reflect continuing operations, excluding discontinued operations related to the sale and exit of the Company’s hemp/cannabis business in late 2023, except as noted.
Dollars are in thousands, except per share data or unless otherwise specified.
Forward Looking Statements
Except for historical information, all of the statements, expectations, and assumptions contained herein are forward-looking statements. Forward-looking statements typically contain terms such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Forward looking statements include, but are not limited to, statements regarding (i) our ability to continue as a going concern, (ii) our ability to become profitable, (iii) our ability to remain listed on NASDAQ (iv) our financial and operating performance, (v) our strategic alternatives, including our cost savings initiatives, (vi) our expectations regarding regulatory enforcement (vii) our products, and (viii) the volatility of our common stock. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in our Annual Report on Form 10-K filed on March 26, 2026. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events, or otherwise, except as otherwise required by law. All information provided in this quarterly report is as of the date hereof, and we assume no obligation to and do not intend to update these forward-looking statements, except as required by law.
Our Business
22nd Century Group, Inc. (NASDAQ: XXII) is a tobacco products company focused on tobacco harm reduction by offering tobacco products with 95% less nicotine, designed to improve health and wellness by giving smokers a choice to control their nicotine consumption. Backed by comprehensive and extensively patented technologies that regulate nicotine biosynthesis activities in the tobacco plant, the Company has pioneered development of high-yield, proprietary reduced nicotine content (RNC) tobacco plants and clinically validated RNC cigarette products. The Company received the first and only FDA Modified Risk Tobacco Product (MRTP) authorization for a combustible cigarette in December 2021. The Company is a subsequent participating manufacturer under the Master Settlement Agreement ("MSA") and vertically integrated for the production of both its own products and contract manufacturing operations ("CMO"), which consist primarily of branded filtered cigars and conventional cigarettes.
Financial Overview
- Net revenues for the second quarter of 2026 were $2,864, a decrease of 29.9% from $4,083 in the prior year period.
- Second quarter 2026 cartons sold of 151 compared to 779 in the comparable prior year period, primarily due to our strategic shift away from high volume and low priced CMO export customers.
- Gross loss for the second quarter of 2026 was a loss of $293 compared to a loss of $635 in the prior year period, reflecting write-off of aged inventory discontinued by our customers of $196, offset by a one-time adjustment to excise taxes of $692.
- Total operating expenses for the second quarter of 2026 increased to $2,998 compared to $2,346 in the prior year period driven by:
- Sales, general and administrative expenses increased to $2,703 compared to $2,119 in the prior year period, primarily driven by higher compensation and benefits, legal and other expenses offset by lower strategic consulting and insurance costs.
- Research development expenses increased to $295, compared to $227 in the prior year period, mainly driven by higher compensation and benefits and lower contract, IP and other expenses.
- Operating loss from continuing operations for the second quarter 2026 was $3,291, compared to a loss of $2,981 in the prior year period, primarily as a result of decreased revenue and volume.
- Net loss from continuing operations in the second quarter of 2026 was $3,265 and basic and diluted loss from continuing operations per common share was $15.60 compared with net loss from continuing operations in the second quarter of 2025 of $3,296, and basic and diluted net loss from continuing operations per common share of $3,279.60.
- As of June 30, 2026, the Company had $6,058 in cash and cash equivalents.
- On August 13, 2026, the Company entered into an amendment with the holders of all of the outstanding June 2026 Inducement Warrants whereby the exercise price was reduced to $0.3675 and to allow all of the June 2026 Inducement Warrants to be exercised on a cashless basis. Following the amendment, all 3,019,586 warrants were exercised on a cashless basis for an aggregate of 2,742,397 shares of common stock, with 2,531,242 of such shares held in abeyance. Following the exercise, no warrants remain outstanding.
Our Financial Results
Three Months Ended June 30, 2026 Compared to Three Months Ended June 30, 2025
| | | Three Months Ended June 30 2026 | | June 30 2025 | | Change $% | | |
|---|---|---|---|---|---|---|---|---|
| Revenues, net | | $2,864 | | $4,083 | | (1,219) | | (29.9) |
| Cost of goods sold | | 1,621 | | 2,863 | | (1,242) | | (43.4) |
| Excise taxes and fees on products | | 1,536 | | 1,855 | | (319) | | (17.2) |
| Gross loss | | (293) | | (635) | | 342 | | (53.9) |
| Gross loss as a % of revenues, net | | (10.2)% | | (15.6)% | | | | |
| Operating expenses: | | | | | | | | |
| Sales, general and administrative ("SG&A") | | 2,703 | | 2,119 | | 584 | | 27.6 |
| SG&A as a % of revenues, net | | 94.4% | | 51.9% | | | | |
| Research and development ("R&D") | | 295 | | 227 | | 68 | | 30.0 |
| R&D as a % of revenues, net | | 10.3% | | 5.5% | | | | |
| Total operating expenses | | 2,998 | | 2,346 | | 652 | | 27.8 |
| Operating loss from continuing operations | | (3,291) | | (2,981) | | (310) | | 10.4 |
| Operating loss as a % of revenues, net | | (114.9)% | | (73.0)% | | | | |
| Other income (expense): | | | | | | | | |
| Other expense | | - | | (12) | | 12 | | (100.0) |
| Interest income | | 43 | | 14 | | 29 | | 207.1 |
| Interest expense | | (17) | | (351) | | 334 | | (95.2) |
| Total other income (expense), net | | 26 | | (349) | | 375 | | (107.4) |
| Loss from continuing operations before income taxes | | (3,265) | | (3,330) | | 65 | | (2.0) |
| (Benefit) provision for income taxes | | - | | (34) | | 34 | | (100.0) |
| Net loss from continuing operations | | $(3,265) | | $(3,296) | | 31 | | (0.9) |
| Net loss as a % of revenues, net | | (114.0)% | | (80.7)% | | | | |
| Net loss per common share from continuing operations (basic and diluted) | | $(15.60) | | $(3,279.60) | | 3,264.00 | | (99.5) |
| | | | | | | | | |
28
Six Months Ended June 30, 2026 Compared to Six Months Ended June 30, 2025
| | | Six Months Ended June 30 2026 | | June 30 2025 | | Change $% | | |
|---|---|---|---|---|---|---|---|---|
| Revenues, net | | $6,970 | | $10,039 | | (3,069) | | (30.6) |
| Cost of goods sold | | 3,546 | | 5,747 | | (2,201) | | (38.3) |
| Excise taxes and fees on products | | 4,351 | | 5,536 | | (1,185) | | (21.4) |
| Gross loss | | (927) | | (1,244) | | 317 | | (25.5) |
| Gross loss as a % of revenues, net | | (13.3)% | | (12.4)% | | | | |
| Operating expenses: | | | | | | | | |
| Sales, general and administrative ("SG&A") | | 4,822 | | 3,918 | | 904 | | 23.1 |
| SG&A as a % of revenues, net | | 69.2% | | 39.0% | | | | |
| Research and development ("R&D") | | 580 | | 390 | | 190 | | 48.7 |
| R&D as a % of revenues, net | | 8.3% | | 3.9% | | | | |
| Total operating expenses | | 5,402 | | 4,308 | | 1,094 | | 25.4 |
| Operating loss from continuing operations | | (6,329) | | (5,552) | | (777) | | 14.0 |
| Operating loss as a % of revenues, net | | (90.8)% | | (55.3)% | | | | |
| Other income (expense): | | | | | | | | |
| Other expense | | - | | (174) | | 174 | | (100.0) |
| Interest income | | 74 | | 30 | | 44 | | 146.7 |
| Interest expense | | (29) | | (909) | | 880 | | (96.8) |
| Total other income (expense), net | | 45 | | (1,053) | | 1,098 | | (104.3) |
| Loss from continuing operations before income taxes | | (6,284) | | (6,605) | | 321 | | (4.9) |
| (Benefit) provision for income taxes | | - | | (34) | | 34 | | (100.0) |
| Net loss from continuing operations | | (6,284) | | (6,571) | | 287 | | (4.4) |
| Net loss as a % of revenues, net | | (90.2)% | | (65.5)% | | | | |
| Net loss per common share from continuing operations (basic and diluted) | | $(52.33) | | $(9,267.98) | | 9,215.65 | | (99.4) |
| | | | | | | | | |
Product line revenue, net
| Contract manufacturing | | Three Months Ended June 30, 2026 $Cartons | | | 2025 $Cartons | | | Change $Cartons | |
|---|---|---|---|---|---|---|---|---|---|
| Cigarettes | | 2,297 | 93 | | 2,715 | 594 | | (418) | (501) |
| Filtered cigars | | 692 | 87 | | 1,319 | 172 | | (627) | (85) |
| Other tobacco products | | (151) | (29) | | 94 | 14 | | (245) | (43) |
| Total contract manufacturing | | 2,838 | 151 | | 4,128 | 780 | | (1,290) | (629) |
| VLN® | | 26 | - | | (45) | (1) | | 71 | 1 |
| Total product line revenues | | 2,864 | 151 | | 4,083 | 779 | | (1,219) | (628) |
| | | | | | | | | | |
| Contract manufacturing | | Six Months Ended June 30, 2026 $Cartons | | | 2025 $Cartons | | | Change $Cartons | |
|---|---|---|---|---|---|---|---|---|---|
| Cigarettes | | 5,144 | 211 | | 7,729 | 1,025 | | (2,585) | (814) |
| Filtered cigars | | 1,565 | 200 | | 2,422 | 331 | | (857) | (131) |
| Other tobacco products | | 238 | 15 | | 88 | 14 | | 150 | 1 |
| Total contract manufacturing | | 6,947 | 426 | | 10,239 | 1,370 | | (3,292) | (944) |
| VLN® | | 23 | 1 | | (200) | (3) | | 223 | 4 |
| Total product line revenues | | 6,970 | 427 | | 10,039 | 1,367 | | (3,069) | (940) |
For the second quarter and six months ended June 30, 2026, total product line revenues decreased to $2,864 and $6,970, respectively, compared to $4,083 and $10,039, respectively, in the prior year periods, as follows:
- For the three and six months ended June 30, 2026, cigarette volume decreased due to our strategic shift away from high volume and low priced CMO export customers as compared to the prior year periods, which accounted for 495 cartons and 747 cartons, respectively.
- For the second quarter and six months ended June 30, 2026, filtered cigars net revenues decreased to $692 and $1,565, respectively, from the prior comparable period, reflecting lower volumes as the Company implemented repricing of customer contracts and shifts in its product mix into higher margin branded cigarettes, including natural styles, and VLN® cigarettes.
- Other tobacco products include new moist snuff sales of $104 and $493 for the three and six months ended June 30, 2026, respectively, compared to none in the prior year comparable periods. These new sales were offset by the reversal of $255 related to obsolete cigarillo products.
- VLN® cigarette net revenues reflect growing reorder activity primarily for our Pinnacle® partner brand VLN® products, offset by current period price promotions targeting expanded awareness, consumer trial and adoption. Additionally, net revenue reflects accruals for product previously sold in prior years that will be returned or exchanged.
Gross (loss) profit
| | | Three Months Ended June 30 2026 | June 30 2025 | Six Months Ended June 30 2026 | | June 30 2025 |
|---|---|---|---|---|---|---|
| Gross loss | | $(293) | $(635) | $(927) | | $(1,244) |
| Percent of Revenues, net | | (10.2)% | (15.6)% | (13.3)% | | (12.4)% |
Gross loss for the three and six-month periods ended June 30, 2026, decreased as compared to the prior year comparable periods benefitting from manufacturing overhead cost savings initiatives implemented by management in second half 2025, offset by decreased volume as compared to the prior year comparable period. Additionally, the three and six-month periods ended June 30, 2026 reflected one-time charges for write-off of aged inventory discontinued by our customers of $196, offset by a one-time recovery of excise taxes of $692 related to settlement with states for non-participating manufacturers credits under the master settlement agreement related to prior tax periods.
Sales, general and administrative (“SG&A”) expense
| | | Changes From Prior Year Three Months Ended | | Six Months Ended |
|---|---|---|---|---|
| Compensation and benefits (a) | | $744 | | $1,066 |
| Strategic consulting (b) | | (189) | | (389) |
| Legal (c) | | 21 | | 73 |
| Insurance (d) | | (41) | | (65) |
| Other expenses | | 49 | | 219 |
| Net increase in SG&A expenses | | $584 | | $904 |
(a) Compensation and benefits expense increased for the three and six months ended June 30, 2026, compared to the prior year periods due to an increase in headcount, benefit premiums, equity and incentive compensation expense.
(b) Strategic consulting costs decreased for the three and six months ended June 30, 2026, compared to the prior year periods due to decreased spending related to investor relations services and FDA post-market studies offset by increased regulatory and consulting expenses.
(c) Legal expenses increased for the three and six months ended June 30, 2026 compared to 2025 mainly due to higher tobacco regulatory legal spend related to compared to the prior year periods.
(d) Insurance costs decreased for the three and six months ended June 30, 2026 compared to the prior year periods due to lower insurance premiums.
Research and development (“R&D”) expense
| | | Changes From Prior Year Three Months Ended | | Six Months Ended |
|---|---|---|---|---|
| Compensation and benefits (a) | | $125 | | $197 |
| Contract, IP and other expenses (b) | | (57) | | (7) |
| Net increase in R&D expenses | | $68 | | $190 |
(a) Increased compensation and benefits for the three and six months ended June 30, 2026, are mainly related to an increase in headcount, benefit premiums and equity compensation expenses in the current year period compared to the prior year periods.
(b) Decreased Contract, IP and other expenses decreased for the three months ended June 30, 2026, compared to the prior year period were primarily due to lower amortization expenses and testing expenses for new product development.
Decreased Contract, IP and other expenses for the six months ended June 30, 2026, compared to the prior year period were due to lower amortization expense offset by increased contract costs.
Other income (expense)
| | | Changes From Prior Year Three Months Ended | | Six Months Ended |
|---|---|---|---|---|
| Other expense (a) | | $12 | | $174 |
| Interest income | | 29 | | 44 |
| Interest expense (b) | | 334 | | 880 |
| Net decrease in other expense | | $375 | | $1,098 |
(a) Other expense decreased for the three and six months ended June 30, 2026, compared to the same prior year periods, due to a loss resulting from change in fair value of the Omnia 2024 warrant liabilities that did not occur in the current year periods.
(b) Decreases in interest expense was a result of repayment of debt obligations on our balance sheet.
For the three months ended June 30, 2026 compared to the prior year period, interest decreased $214 and $129 of extinguishment charges that occurred in the prior year period from the Senior Secured Credit Facility; which was repaid in September 2025. These decreases were offset by interest expense of $9 related to the NCSU Promissory Note.
For the six months ended June 30, 2026 compared to the prior year period, interest decreased $768 and $129 of extinguishment charges that occurred in the prior year period from the Senior Secured Credit Facility; which was repaid in September 2025. In addition, other interest expense charges decreased by $4 offset by an increase of $21 related to the NCSU Promissory Note.
Liquidity and Capital Resources
We have incurred significant losses and negative cash flows from operations since inception and expect to incur additional losses until such time that we can generate significant revenue and profit in our tobacco business. We had negative cash flow from operations of $7,092 for the six months ended June 30, 2026 and an accumulated deficit of $405,532 as of June 30, 2026. As of June 30, 2026, we had cash and cash equivalents of $6,058 and working capital from continuing operations of $10,365 (compared to working capital from continuing operations of $10,359 at December 31, 2025). Given our projected operating requirements and existing cash and cash equivalents, there is substantial doubt about our ability to continue as a going concern through one year following the date that the Condensed Consolidated Financial Statements herein are issued.
In response to these conditions, management is currently evaluating different strategies for reducing expenses, as well as pursuing financing strategies which include raising additional funds through the issuance of securities, asset sales, and through arrangements with strategic partners. If capital is not available to the Company when, and in the amounts needed, it could be required to liquidate inventory or assets, cease or curtail operations, seek to negotiate new business deals with our business partners or seek protection under applicable bankruptcy laws or similar state proceedings. There can be no assurance that the Company will be able to raise the capital it needs to continue operations. Accordingly, there is substantial doubt regarding our ability to continue in operations. Management’s plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern through one year following the date that the Condensed Consolidated Financial Statements are issued.
Our cash and cash equivalents and working capital from continuing operations as of June 30, 2026 and December 31, 2025 are set forth below:
| | | June 30 2026 | | December 31 2025 |
|---|---|---|---|---|
| Cash and cash equivalents | | $6,058 | | $7,149 |
| Working capital | | $10,365 | $10,359 |
Working Capital
As of June 30, 2026, we had working capital from continuing operations of approximately $10,365 compared to working capital of approximately $10,359 at December 31, 2025, an increase of $6. This increase in working capital was primarily due to a decrease in net current liabilities of $818, offset by a decrease in net current assets of $812. Cash and cash equivalents decreased by $1,091 and the remaining net current assets increased by $279. Management continues to take further steps to improve liquidity more. Refer below to “Cash demands on operations.”
Summary of Cash Flows
| Cash provided by (used in): | | Six Months Ended June 30, 2026 | | 2025 | | Change $ |
|---|---|---|---|---|---|---|
| Operating activities | | $(7,092) | | $(6,454) | | (638) |
| Investing activities | | (357) | 672 | | (1,029) | |
| Financing activities | | 6,358 | 4,443 | | 1,915 | |
| Net change in cash and cash equivalents | | $(1,091) | $(1,339) | | |
Net cash used in operating activities
Cash used in operating activities increased $638 from $6,454 in 2025 to $7,092 in 2026. The primary driver for this change was an increase in cash used for working capital components related to operations in the amount of $539, offset by lower net loss of $1,128 and a decrease of $1,227 related to net adjustments to reconcile net loss to cash for the six months ended June 30, 2026, as compared to the six months ended June 30, 2025.
Net cash used in (provided by) investing activities
Cash used in investing activities amounted to $357 for the six months ended June 30, 2026, as compared to cash provided by investing activities of $672 for the six months ended June 30, 2025. The decrease in cash provided by investing activities of $1,029 was the result of $770 of proceeds from the sale of property, plant and equipment primarily from the sale of Needlerock farms that occurred in the prior year period, $25 received from the 2025 GVB promissory note in the current year period and an increase of cash outflows of $284 related to the acquisitions of patents, trademarks, licenses and property, plant and equipment.
Net cash provided by financing activities
During the six months ended June 30, 2026, cash provided by financing activities increased by $1,915 compared to $4,443 in the prior year period to $6,358 in the current year period, resulting from increases in net proceeds from Series B convertible preferred stock issuances of $15,299, net proceeds from issuance of common stock related to the ATM of $64, decreases of cash outflows from payments on long-term debt of $1,017 and notes payable of $190, offset by a decrease in cash inflows of $221 for proceeds from issuance of note payable and from net proceeds of warrant exercises of $2,766, cash outflows from the redemption of Series A at par value of $9,650, redemption of Series B at par value of $2,010, and principal payments for finance leases of $8.
Cash demands on operations
We have financed our operations to date primarily through the issuance of equity securities, proceeds from the exercise of warrants to purchase common stock and sale of debt instruments with various institutions, accredited investors, high net worth individuals and creditors.
In June 2026, we received net proceeds of $2,309 from the inducement and exercise of 267,651 existing warrants for shares of common stock and issuance of 267,284 warrants to purchase common stock. The Company utilized a portion of the net proceeds to repurchase at par 2,010 shares of Series B convertible preferred stock in the amount of $2,010.
In March 2026, we issued 16,000 shares of Series B convertible preferred stock and 233,481 warrants to purchase shares of common stock for net proceeds of $15,275, of which $9,650 was used to repurchase at par all of the remaining share of outstanding Series A convertible preferred stock issued in August 2025. The investors from the Series B convertible preferred stock offering have an additional 4,000 shares that may be purchased at subsequent closings, of which 25 shares have been purchased through June 30, 2026.
We entered into a sales agreement (the “Sales Agreement”) with Needham & Company, LLC (the “Sales Agent”) which permits us to sell up to $25,000 of our common stock from time to time at prevailing market prices, which program was reduced to a maximum of $6,400 on May 1, 2026. No sales have occurred under the ATM program for the three months ended June 30, 2026. During the six months ended June 30, 2026, the Company sold 2,221 shares of common stock under the ATM Program for gross proceeds of $200. The Company paid fees to the Sales Agent in the amount of $6.
Outstanding Warrants
On August 13, 2026, the Company entered into an amendment with the holders of all of the outstanding June 2026 Inducement Warrants whereby the exercise price was reduced to $0.3675 and to allow all of the June 2026 Inducement Warrants to be exercised on a cashless basis. Following the amendment, all 3,019,586 warrants were exercised on a cashless basis for an aggregate of 2,742,397 shares of common stock, with 2,531,242 of such shares held in abeyance. Following the exercise, no warrants remain outstanding.
Critical Accounting Policies and Estimates
The preparation of our Condensed Consolidated Financial Statements in accordance with accounting principles generally accepted in the U.S. requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements and accompanying notes. Our estimates, assumptions and judgments are based on historical experience and various other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying amount of assets and liabilities that are not readily apparent from other sources. Making estimates, assumptions and judgments about future events is inherently unpredictable and is subject to significant uncertainties, some of which are beyond our control. Management believes the estimates, assumptions and judgments employed and resulting balances reported in the Condensed Consolidated Financial Statements are reasonable; however, actual results could differ materially.
There have been no material changes to the information set forth in our Annual Report on Form 10-K for the year ended December 31, 2025.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements as defined by Item 303(a)(4) of Regulation S-K.
Market risk
As filed, 136 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
There have been no material changes to the information set forth in our Annual Report on Form 10-K for the year ended December 31, 2025.
Controls and procedures
As filed, 1,858 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
(a) Evaluation of Disclosure Controls and Procedures:
The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in its Securities Exchange Act of 1934 (“Exchange Act”) reports are recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including the Company’s chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Our chief executive officer and chief financial officer, after evaluating the effectiveness of the Company’s “disclosure controls and procedures” (as defined in the Exchange Act Rules 13a-15(e) or 15d-15(e)) as of the end of the period covered by this quarterly report, have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Form 10-Q to ensure information required to be disclosed is recorded, processed, summarized and reported within the time period specified by SEC rules, based on their evaluation of these controls and procedures as required by paragraph (b) of Exchange Act Rules 13a-15 or 15d-15.
(b) Changes in Internal Control over Financial Reporting:
There were no changes in our internal control over financial reporting during the quarter ended June 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 6,052 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Except as set forth below, there have been no material changes from the risk factors disclosed in Item 1A of Part I of our Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 26, 2026.
Nasdaq may delist our common stock from trading on its exchange, which could limit investors’ ability to make transactions in our common stock, reduce the liquidity of our common stock and materially impair our ability to raise the additional capital necessary to continue our operations.
Our common stock is currently listed on the Nasdaq Capital Market (“Nasdaq”). To maintain that listing, we must satisfy Nasdaq’s continued listing requirements, including requirements relating to the minimum bid price of our common stock, the market value of our listed securities, stockholders’ equity, the market value of our publicly held shares, the number of publicly held shares and public holders, corporate governance and other matters. We cannot assure you that we will continue to satisfy all applicable Nasdaq continued listing requirements.
Under Nasdaq Listing Rule 5550(a)(2), the closing bid price of our common stock generally must be at least $1.00 per share. If the closing bid price is below $1.00 per share for 30 consecutive business days, Nasdaq may notify us that we no longer comply with the minimum bid-price requirement. Although Nasdaq’s rules may provide an eligible company with a compliance period in which to regain compliance, there can be no assurance that we would be eligible for any such period, that Nasdaq would grant us any additional time, or that we would regain or subsequently maintain compliance. Regaining compliance may require the closing bid price of our common stock to equal or exceed $1.00 per share for a specified number of consecutive business days, and Nasdaq may require a longer compliance period in its discretion.
Nasdaq has adopted a continued listing requirement that requires companies listed on the Nasdaq Capital Market to maintain a minimum market value of listed securities (“MVLS”) of at least $5 million. Under the rule, if a company’s MVLS remains below $5 million for 30 consecutive business days, Nasdaq may issue a Staff Delisting Determination without providing the company with the traditional cure or compliance period available for certain other listing deficiencies. The rule also provides for the suspension of trading in the company’s securities during the pendency of an appeal of the Staff Delisting Determination, subject to the applicable Nasdaq rules and procedures. Although the new MVLS rule has been stayed by the SEC, we cannot predict whether the SEC will affirm, modify or set aside the rule, whether Nasdaq will further amend the rule, or when or whether the rule will again become effective. The stay could be lifted with little advance notice, and the rule could become applicable to us in its current or a modified form. If the stay is lifted and the rule becomes operative in its current or a substantially similar form, and our MVLS subsequently remains below $5 million for the applicable measurement period, our common stock could be suspended from trading and delisted without a traditional cure period.
During the past two years, we have received deficiency letters from the Nasdaq Listing Qualifications Department notifying us that we were not in compliance with certain Nasdaq continued listing requirements. Although we addressed those deficiencies and regained compliance, our prior compliance does not provide assurance that we will maintain compliance in the future. We may receive additional deficiency or delisting notices, and any compliance period or exception available under Nasdaq’s rules may be insufficient for us to regain compliance. Nasdaq may also amend its listing standards, adopt more stringent standards or alter the remedies available to a company that fails to comply.
If Nasdaq delists our common stock from trading on its exchange, we could face significant material adverse consequences, including:
- limited availability of market quotations for our common stock;
- reduced liquidity with respect to our securities;
- a determination that shares of our common stock constitute “penny stock,” which would require brokers trading in our shares to comply with more stringent rules and could result in a reduced level of trading activity in the secondary trading market for our shares;
- a limited amount of news, securities-analyst and institutional-investor coverage;
- increased price volatility and wider bid-and-ask spreads;
- the possible loss of confidence by investors, employees, customers, suppliers and other business partners;
- reduced ability of investors to dispose of their shares or obtain accurate quotations regarding the market value of our common stock; and
- a decreased ability to issue additional common stock, use our securities as acquisition consideration or obtain additional financing in the future.
A delisting or trading suspension could also materially impair our ability to raise capital. We have incurred significant losses and may require additional capital to fund our operations, satisfy our obligations, execute our business strategy and continue as a going concern. Investors may be unwilling to purchase our securities if they are not listed on a national securities exchange, and any financing that remains available may involve substantially higher costs, more restrictive terms, significant discounts, warrant coverage, senior or secured securities, or substantial dilution to existing stockholders. Delisting could also impair our ability to use an effective registration statement, access at-the-market or other public equity programs, or satisfy exchange-related conditions in existing or future financing agreements.
The occurrence of any of these events could materially and adversely affect the value and liquidity of our common stock, our business, financial condition and results of operations, and our ability to continue as a going concern.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2026-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2026-04-01 to 2026-06-30 | $2.9m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Revenue | 6 months2026-01-01 to 2026-06-30 | $7.0m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months2026-04-01 to 2026-06-30 | $1.6m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2026-01-01 to 2026-06-30 | $3.5m | us-gaap:CostOfRevenue |
| Research and development | 3 months2026-04-01 to 2026-06-30 | $295.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2026-01-01 to 2026-06-30 | $580.0k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2026-04-01 to 2026-06-30 | $2.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2026-01-01 to 2026-06-30 | $4.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2026-04-01 to 2026-06-30 | −$3.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2026-01-01 to 2026-06-30 | −$6.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2026-04-01 to 2026-06-30 | $17.0k | us-gaap:InterestExpenseNonoperating |
| Interest expense | 6 months2026-01-01 to 2026-06-30 | $29.0k | us-gaap:InterestExpenseNonoperating |
| Net income | 3 months2026-04-01 to 2026-06-30 | −$3.3m | us-gaap:NetIncomeLoss |
| Net income | 6 months2026-01-01 to 2026-06-30 | −$6.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2026-04-01 to 2026-06-30 | −$104.00 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2026-01-01 to 2026-06-30 | −$270.84 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2026-04-01 to 2026-06-30 | −$104.00 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2026-01-01 to 2026-06-30 | −$270.84 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2026-04-01 to 2026-06-30 | 209,241 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2026-01-01 to 2026-06-30 | 120,095 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2026-01-01 to 2026-06-30 | −$7.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2026-01-01 to 2026-06-30 | $371.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2026-06-30 | $6.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2026-06-30 | $16.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2026-06-30 | $26.2m | us-gaap:Assets |
| Current liabilities | At period end2026-06-30 | $6.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2026-06-30 | $7.5m | us-gaap:Liabilities |
| Shareholders' equity | At period end2026-06-30 | $18.6m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001104659-26-097172. Last ingested by Listed: Nov 3, 2026, 12:54 ET. Listed shows no prices and gives no investment advice.